The imminent patent expiration of Keytruda (pembrolizumab), the world’s best-selling drug, has sparked a fierce competition between South Korea’s leading biotech firms, Samsung Bioepis and Celltrion. This contest focuses on the lucrative immuno-oncology biosimilar market, valued at 44 trillion won ($31.9 billion). Samsung Bioepis has taken the lead by completing a significant global Phase 3 trial and filing preemptive regulatory applications, while Celltrion is now actively pursuing approval for its own biosimilar.
Celltrion’s Entry into the Race
Celltrion recently submitted an application for domestic product approval for its Keytruda biosimilar, designated CT-P51, to the Ministry of Food and Drug Safety. The company demonstrated pharmacokinetic equivalence to the original Keytruda through a trial involving 228 melanoma patients who had undergone surgery. The results confirmed safety and immunogenicity comparable to the original drug. Following the domestic approval, Celltrion plans to seek regulatory approvals from major global bodies, including the US Food and Drug Administration and the European Medicines Agency, as it aims to close the gap with its competitor.
Samsung Bioepis: The Front-Runner
Samsung Bioepis has established itself as the front-runner in the global development race. It successfully completed its global Phase 3 trial for the Keytruda biosimilar SB27 before its competitors and has proactively filed applications with key regulatory authorities. The multinational trial included over 600 patients with non-small cell lung cancer, which represents a significant portion of Keytruda’s total sales. The study’s robust efficacy and safety data are expected to bolster the company’s position among prescribers worldwide.
Market Dynamics and Competitive Strategies
Keytruda, developed by Merck, achieved global sales of approximately $31.7 billion in the last year, reinforcing its status as the leading immuno-oncology drug. The competition to launch a biosimilar coincides with Keytruda’s patent expiration, creating a race for market share. The first biosimilar to hit the market is poised to capture considerable early prescriptions, establishing a strong foothold in a highly lucrative sector.
Samsung Bioepis’s commercialization strategy focuses on rapid market-share acquisition by leveraging established local marketing networks and distribution partnerships with global leaders such as Organon, Biogen, and Sandoz. With a proven history of launching successful biosimilars, Samsung aims to secure key prescription channels across the United States and Europe.
Conversely, Celltrion is banking on its cost-effectiveness, supported by large-scale production capabilities and direct sales networks in the US and Europe. The company plans to create synergies by pairing its Keytruda biosimilar with its own treatment, Vegzelma, used for ovarian and cervical cancers. Additionally, Celltrion is engaging in negotiations with pharmacy benefit managers in the US to enhance its market presence.
Increasing Competition and Legal Strategies
The competition for the Keytruda biosimilar market is intensifying, with global players such as Sandoz, Amgen, and Coherus entering the fray. The quest for first-mover advantage, coupled with patent disputes and launch rivalries, is likely to escalate. South Korean firms are also developing legal and regulatory strategies to facilitate early market entry aligned with patent expirations while countering the originator’s patent defenses.
A New Era for K-Biosimilars
The contest between Samsung Bioepis and Celltrion represents a significant evolution in the South Korean biosimilar landscape, which has traditionally focused on therapies for autoimmune diseases. The shift into the high-stakes immuno-oncology market underscores the growing capabilities of these biotech companies.
As they leverage distinct clinical development strategies and global commercialization expertise, the eyes of the industry are on whether these South Korean firms can lead the way in the next generation of blockbuster biosimilars.
Key Takeaways
- Samsung Bioepis is currently leading the race with its advanced Phase 3 trial and preemptive regulatory filings.
- Celltrion has entered the competition with its application for Keytruda biosimilar CT-P51, aiming to establish its presence in the market.
-
The competition for the Keytruda biosimilar market involves significant strategies focusing on rapid market share capture and cost competitiveness.
-
Global players are intensifying their efforts, promising a dynamic and competitive landscape as the patent expiration approaches.
In conclusion, the race for the Keytruda biosimilar market is not just a battle between two companies; it represents a pivotal moment for the future of biosimilars in oncology. The outcome will likely set the standard for the industry, shaping the trajectory for South Korean biotech companies and their global aspirations.
Read more → biz.heraldcorp.com